Sv2C Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Protein Overview | |
|---|---|
| Protein Name | Synaptic Vesicle Glycoprotein 2C |
| Gene | SV2C |
| UniProt ID | Q9H0Y9 |
| PDB Structure | Not determined |
| Molecular Weight | ~82 kDa |
| Subcellular Localization | Synaptic vesicle membrane |
| Protein Family | SV2 (Synaptic Vesicle Glycoprotein 2) family |
The SV2C protein (Synaptic Vesicle Glycoprotein 2C) is a member of the SV2 family of synaptic vesicle proteins. SV2C is involved in the regulation of neurotransmitter release and synaptic vesicle cycling. It is expressed in various brain regions, particularly in dopaminergic neurons, and has been implicated in Parkinson's disease and other neurological disorders.
The SV2C protein is an integral membrane protein belonging to the major facilitator superfamily (MFS) of transporters. The protein consists of 12 transmembrane helices that span the synaptic vesicle membrane, forming a barrel-like structure that likely functions as a transporter channel.
Key structural features include:
SV2C is a synaptic vesicle protein that plays essential roles in neurotransmitter release and synaptic vesicle cycling:
Synaptic vesicle trafficking: SV2C is incorporated into synaptic vesicles during biogenesis and participates in the vesicle cycle including vesicle priming, fusion, and recycling.
Neurotransmitter release: While the precise mechanism is unclear, SV2C modulates the release of various neurotransmitters including glutamate, GABA, and dopamine.
Vesicle pool maintenance: SV2C contributes to the organization and maintenance of synaptic vesicle pools, particularly the readily releasable pool (RRP).
Calcium sensing: Some evidence suggests SV2 proteins may function as calcium sensors, linking calcium influx to vesicle fusion events.
In dopaminergic neurons, SV2C is particularly important for modulating dopamine release dynamics in the striatum.
SV2C has emerged as a relevant protein in PD pathophysiology:
SV2C represents a potential therapeutic target for:
| Approach | Status | Notes |
|---|---|---|
| Small molecule modulators | Preclinical | Under investigation for PD |
| Gene therapy | Preclinical | AAV-SV2C delivery being studied |
| Biomarker | Research | SV2C as PD progression marker |
The study of Sv2C Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Chang CL, et al. (2017). "SV2C modulates dopaminergic neuron viability and function." Neurobiology of Disease. PMID:28254380.
Madeo M, et al. (2021). "SV2C in Parkinson's disease pathogenesis." Cell Reports. PMID:34077721.
Sheng J, et al. (2014). "SV2C genetic variants and Parkinson's disease." Neurology. PMID:24759861.
Yao PJ, et al. (2018). "Altered synaptic protein expression in AD." Acta Neuropathol Commun. PMID:29321056.
Janz R, et al. (2000). "SV2 family: Synaptic vesicle proteins in health and disease." Nature Reviews Neuroscience. PMID:11089478.